Agile Therapeutics, Inc.
NASDAQ: AGRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Alfred F. Altomari
- Employees
- 19
- Headquarters
- Princeton, United States
- IPO year
- 2014
- Market cap
- $10.4M
- Website
- https://www.agiletherapeutics.com
Loading AGRX…
Loading profile data…Frequently asked questions about AGRX
What does Agile Therapeutics, Inc. (AGRX) do?
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. Th...
Where does AGRX trade?
Agile Therapeutics, Inc. (AGRX) trades on the NASDAQ Capital Market.
What sector is AGRX in?
Agile Therapeutics, Inc. (AGRX) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Agile Therapeutics, Inc.?
Alfred F. Altomari is the chief executive officer of Agile Therapeutics, Inc. (AGRX).
Where is Agile Therapeutics, Inc. headquartered?
Agile Therapeutics, Inc. is headquartered in United States.
Does AGRX pay a dividend?
Agile Therapeutics, Inc. (AGRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AGRX go public?
Agile Therapeutics, Inc. (AGRX) completed its initial public offering in 2014.